US EditionAstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
UNITED STATES, JUL 21 – AstraZeneca aims to create tens of thousands of U.S. jobs and increase its U.S. revenue share to 50% by 2030 through advanced manufacturing and R&D investments.
- On July 21, 2025, AstraZeneca announced plans to invest $50 billion by 2030 to expand manufacturing and research in the U.S., including a new Virginia facility.
- This large investment follows sustained U.S. tariffs and political pressure from President Trump urging pharmaceutical companies to increase domestic production, as explained by Commerce Secretary Howard Lutnick.
- The Virginia facility will be AstraZeneca's largest manufacturing investment worldwide, producing active ingredients for weight management and cholesterol medicines, while expansions will cover five other U.S. states.
- AstraZeneca CEO Pascal Soriot stated that the funding initiative aligns with the company’s target to generate $80 billion in yearly sales by 2030, with approximately 50% expected to originate from the U.S. Meanwhile, Commerce Secretary Howard Lutnick described the investment as a landmark move that will create tens of thousands of employment opportunities.
- The investment signals AstraZeneca's prioritization of the U.S. market, reacting to tariff policies and industry pressures, and follows similar commitments by other top drugmakers to boost domestic manufacturing and R&D.
205 Articles
205 Articles
MarylandReporter.com
citybizAs Virgina Lands AstraZeneca Facility, Moore Administration Whistles Past The Graveyard
The state of Maryland and the Moore Administration can best be characterized as “whistling past the graveyard” once again … case in point: The Virginia Mercury headline (July 22, 2025) … “AstraZeneca to build its largest-ever manufacturing facility in Virginia, creating hundreds of jobs — Pharmaceutical giant makes record investment as state leaders tout life sciences boom.” The article goes on to say that the investment to be made will be worth…
Delaware’s AstraZeneca site misses out on $50B investment
AstraZeneca's move to invest billions in several sites, namely a new manufacturing facility in Virginia, leaves out plans for its existing Delaware locations for now. The post Delaware’s AstraZeneca site misses out on $50B investment appeared first on Delaware Business Times.
AstraZeneca to build major drug manufacturing facility in Virginia
RICHMOND, Va. UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating hundreds of new jobs as part of a $50 billion investment in the United States by 2030.The exact location within Virginia has not yet been determined, with several sites still under consideration.Governor Glenn Youngkin said the project highlights Virginia's strengths in workforce development and availability of sho…
Coverage Details
Bias Distribution
- 48% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
